<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82130">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687348</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000817-36</org_study_id>
    <secondary_id>2012-05</secondary_id>
    <nct_id>NCT01687348</nct_id>
  </id_info>
  <brief_title>Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy</brief_title>
  <official_title>Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric, open-label study conducted in women requiring mastectomy and
      eligible for tumescent infiltrative anaesthesia.

      Blood samples will be collected during 48h after start of infiltration. Total and free
      lidocaine concentrations measurements will be determined by gas chromatography. Visual
      analogic scale scores to evaluate postoperative pain and all data concerning analgesic drugs
      and adverse effects will be collected.

      Population pharmacokinetic parameters will be estimated using NONMEM software and covariates
      influence on parameters variability will be tested.

      Primary outcome value: Population pharmacokinetic parameters with possible covariates
      influence on variability.

      Patients and period of study: n=30 patients enrolled during 24 months, total study duration:
      30 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of 'drug lidocaine'&quot;</measure>
    <time_frame>36 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
    <description>during tumescent infiltrative anaesthesia for mastectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>analgesic postoperative efficacy</measure>
    <time_frame>36 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mastectomy</condition>
  <arm_group>
    <arm_group_label>lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine aguettant</intervention_name>
    <arm_group_label>lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgery carcinologique of the breast requiring a mastectomy under tumescente local
             anesthetic

          -  Age: upper to 18 years

          -  Weight: upper to 50 kg

        Exclusion Criteria:

          -  Cutaneous infection in the point of draining

          -  Clinical Disorder(Confusion) of the coagulation

          -  Retreat(Withdrawal) of the consent in the course of protocol

          -  Unwanted Effect engraves(burns) requiring the stop(ruling) of the
             treatment(processing)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernard bruguerolle</last_name>
    <email>bernard.bruguerolle@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>bernard bruguerolle</last_name>
      <email>bernard.bruguerolle@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>bernard bruguerolle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 17, 2012</lastchanged_date>
  <firstreceived_date>June 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
